当前位置: 首页 > 详情页

Elucidating the mechanisms of Shenwu Capsule in improving the cognitive decline in aging based on the UPLC-Q-TOF-MS, network pharmacology, and experimental validation

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Pharmacology, Xuanwu Hospital of Capital Medical University, Beijing 100053, China [2]Department of Endocrinology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, China [3]School of Dentistry, University of Michigan, Ann Arbor, MI 48109, USA
出处:
ISSN:

关键词: Shenwu capsule Age-related cognitive decline Network pharmacology UPLC-Q-TOF-MS PI3K/Akt/Bcl-2 signaling pathway Psoralidin

摘要:
Given the growing incidence of dementia-related disorders in the aging population, identifying effective treatments for age-related cognitive decline (ARCD) is crucial. Shenwu Capsule (SWC), shown to have therapeutic efficacy in phase III clinical trials for senile dementia, has unclear mechanisms and active ingredients. Aged mice were administered SWC orally for three months, and behavioral tests, including the Morris water maze, Y maze, and novel object recognition, assessed learning and memory. Neuronal damage was evaluated using histopathology, and the levels of Aβ and phosphorylated tau proteins were measured. UPLC-Q-TOF-MS identified 11 components of SWC capable of crossing the blood-brain barrier (BBB), and network pharmacology was employed to explore their potential mechanisms. Through various detection methods, including transmission electron microscopy, Western blotting, qRT-PCR, ELISA, and immunofluorescence, six key targets (AKT1, TNF, TP53, SRC, EGFR, BCL2) were elucidated. GO and KEGG pathway analyses revealed that the PI3K/Akt signaling pathway plays a crucial role in the pharmacological effects of SWC. SWC was found to suppress neuronal apoptosis by activating the PI3K/Akt/Bcl-2 signaling pathway, as demonstrated by changes in mRNA and protein levels. Histological analysis further showed that SWC treatment restored mitochondrial morphology in the hippocampus of aged mice. Molecular docking simulations confirmed strong binding affinities between the active components and key targets. Psoralidin, a component with strong molecular docking potential, was shown in vitro to activate the PI3K/Akt/Bcl-2 pathway, reduce ROS, decrease apoptosis, improve mitochondrial morphology, and stabilize mitochondrial membrane potential. These protective effects were blocked by the PI3K inhibitor LY294002. Overall, SWC ameliorates ARCD through modulation of the PI3K/Akt/Bcl-2 signaling pathway, with psoralidin identified as a potential active ingredient.Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 3 区 医学
小类 | 2 区 分析化学 3 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 2 区 分析化学 3 区 药学
第一作者:
第一作者机构: [1]Department of Pharmacology, Xuanwu Hospital of Capital Medical University, Beijing 100053, China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:17067 今日访问量:0 总访问量:916 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院